<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00521430</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000561542</org_study_id>
    <secondary_id>AMC-UUCM-2004-0029</secondary_id>
    <nct_id>NCT00521430</nct_id>
  </id_info>
  <brief_title>Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other Disease</brief_title>
  <official_title>NON-T-CELL DEPLETED HLA-HAPLOIDENTICAL FAMILIAL DONOR HEMATOPOIETIC CELL TRANSPLANTATION AFTER REDUCED INTENSITY CONDITIONING</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Giving chemotherapy before a donor stem cell transplant helps stop the growth of&#xD;
      cancer or abnormal cells. It also helps stop the patient's immune system from rejecting the&#xD;
      donor's stem cells. When the healthy stem cells from a donor are infused into the patient&#xD;
      they may help the patient's bone marrow make stem cells, red blood cells, white blood cells,&#xD;
      and platelets. Sometimes the transplanted cells from a donor can make an immune response&#xD;
      against the body's normal cells. Giving cyclosporine and methotrexate before and after&#xD;
      transplant may stop this from happening.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying the side effects and how well donor stem cell&#xD;
      transplant works when given after conditioning therapy in treating patients with hematologic&#xD;
      cancer, recurrent or metastatic solid tumor, or other disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the safety and efficacy of non-T-cell depleted, HLA-haploidentical related&#xD;
           donor hematopoietic stem cell transplantation after a reduced-intensity conditioning&#xD;
           regimen comprising busulfan, fludarabine phosphate, anti-thymocyte globulin, and&#xD;
           methylprednisolone in patients with hematologic cancer, recurrent or metastatic solid&#xD;
           tumors, or other diseases.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
        -  Reduced-intensity conditioning regimen: Patients receive busulfan IV 4 times daily on&#xD;
           days -7 and -6; fludarabine phosphate IV over 30 minutes on days -7 to -2; and&#xD;
           methylprednisolone IV over 30 minutes followed by anti-thymocyte globulin IV over 4&#xD;
           hours on days -4 to -1.&#xD;
&#xD;
        -  Donor hematopoietic stem cell transplantation: Patients receive donor peripheral blood&#xD;
           stem cells IV over 1 hour on days 0 and 1.&#xD;
&#xD;
        -  Graft-versus-host disease (GVHD) prophylaxis: Patients receive cyclosporine IV over 2-4&#xD;
           hours or orally twice daily beginning on day -1 and continuing until day 60, followed by&#xD;
           a taper in the absence of GVHD. Patients also receive methotrexate IV on days 2, 4, 7,&#xD;
           and 12.&#xD;
&#xD;
      After the transplant, patients are followed periodically.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Engraftment (neutrophil, platelet, and red blood cells)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and kinetics of mixed chimerism as assessed by polymerase chain reaction</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and severity of regimen-related toxicities</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of acute and chronic graft-versus-host disease</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Immune reconstitution</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of tumor response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Nonmalignant Neoplasm</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic hematopoietic stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of 1 of the following:&#xD;
&#xD;
               -  High-risk acute leukemia, including any of the following:&#xD;
&#xD;
                    -  Refractory acute leukemia&#xD;
&#xD;
                    -  Acute leukemia beyond first remission&#xD;
&#xD;
                    -  Acute leukemia in first remission with poor prognostic features (e.g.,&#xD;
                       chromosomal changes suggesting poor prognosis)&#xD;
&#xD;
               -  Chronic myelogenous leukemia in second chronic, accelerated, or blastic phase&#xD;
&#xD;
               -  Severe aplastic anemia that is not responsive to immunosuppressive therapy&#xD;
&#xD;
               -  Myelodysplastic syndromes, including any of the following:&#xD;
&#xD;
                    -  Refractory anemia (RA) or RA with ringed sideroblasts with severe cytopenia&#xD;
&#xD;
                    -  RA with excess blasts (RAEB)&#xD;
&#xD;
                    -  RAEB in transformation&#xD;
&#xD;
                    -  Chronic myelomonocytic leukemia&#xD;
&#xD;
               -  Refractory or relapsed non-Hodgkin or Hodgkin lymphoma&#xD;
&#xD;
               -  Multiple myeloma&#xD;
&#xD;
               -  Biopsy proven measurable solid tumor meeting 1 of the following criteria:&#xD;
&#xD;
                    -  Recurrent disease after primary treatment and deemed incurable to standard&#xD;
                       treatment&#xD;
&#xD;
                    -  Metastatic disease for which no known standard therapy that is potentially&#xD;
                       curative or definitely capable of extending life expectancy exists&#xD;
&#xD;
          -  Must have a related HLA-haploidentical mismatched (3/6 or fewer loci) donor available&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Karnofsky performance status 70-100%&#xD;
&#xD;
          -  Bilirubin &lt; 2.0 mg/dL&#xD;
&#xD;
          -  AST &lt; 3 times upper limit of normal&#xD;
&#xD;
          -  Creatinine &lt; 2.0 mg/dL&#xD;
&#xD;
          -  Ejection fraction &gt; 40% by MUGA&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyoo H. Lee, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center - University of Ulsan College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Lee KH, Lee JH, Lee JH, Kim DY, Seol M, Lee YS, Kang YA, Jeon M, Hwang HJ, Jung AR, Kim SH, Yun SC, Shin HJ. Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome. Blood. 2011 Sep 1;118(9):2609-17. doi: 10.1182/blood-2011-02-339838. Epub 2011 Jun 28.</citation>
    <PMID>21715313</PMID>
  </results_reference>
  <verification_date>October 2007</verification_date>
  <study_first_submitted>August 24, 2007</study_first_submitted>
  <study_first_submitted_qc>August 24, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2007</study_first_posted>
  <last_update_submitted>March 25, 2013</last_update_submitted>
  <last_update_submitted_qc>March 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2013</last_update_posted>
  <keyword>recurrent childhood grade III lymphomatoid granulomatosis</keyword>
  <keyword>childhood diffuse large cell lymphoma</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>childhood immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>childhood nasal type extranodal NK/T-cell lymphoma</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>aplastic anemia</keyword>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>childhood acute lymphoblastic leukemia in remission</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>refractory anemia with excess blasts in transformation</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>refractory anemia with ringed sideroblasts</keyword>
  <keyword>refractory anemia</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>angioimmunoblastic T-cell lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
  <keyword>Waldenstr√∂m macroglobulinemia</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>cutaneous B-cell non-Hodgkin lymphoma</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>childhood chronic myelogenous leukemia</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

